Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

γδ T cells maintain sensitivity to immunotherapy in MHC-I-deficient tumors

Nature Immunology volume 24, pages 387–388 (2023)Cite this article

Subjects

Research shows that Vδ1 and Vδ3 γδ T cells that express PD-1 and display potent cytotoxic functions are key immune responders in HLA-class-I-negative colon cancers subjected to immune checkpoint blockade therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ICB in HLA-class-I-deficient colon cancer leads to antitumor responses mediated by cytotoxic γδ T cells.

References

  1. Ijsselsteijn, M. E. et al. Br. J. Cancer 120, 815–818 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. de Vries, N. L. et al. Nature https://doi.org/10.1038/s41586-022-05593-1 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nishino, M. et al. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Silva-Santos, B., Mensurado, S. & Coffelt, S. B. Nat. Rev. Cancer 19, 392–404 (2019).

    Article  CAS  PubMed  Google Scholar 

  5. Mikulak, J. et al. JCI Insight 4, 125884 (2019).

    Article  PubMed  Google Scholar 

  6. Wu, Y. et al. Sci. Transl. Med. 11, eaax9364 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wu, Y. et al. Nat. Cancer 3, 696–709 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. de Vries, N. L. et al. Gut 69, 691–703 (2020).

    Article  PubMed  Google Scholar 

  9. Hoeres, T. et al. Oncoimmunology 8, 1550618 (2019).

    Article  PubMed  Google Scholar 

  10. Rossi, C. et al. Oncoimmunology 8, 1554175 (2019).

    Article  PubMed  Google Scholar 

  11. Nada, M. H. et al. Oncoimmunology 10, 1989789 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Almeida, A. R. et al. Clin. Cancer Res. 22, 5795–5804 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge funding from Fundação para a Ciência e Tecnologia of Portugal’s Ministério da Ciência, Tecnologia e Ensino Superior (PTDC/MED-ONC/6829/2020 to B.S.-S. and 2021.01953.CEECIND to S.M.).

Author information

Authors and Affiliations

  1. Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    Bruno Silva-Santos & Sofia Mensurado

Authors
  1. Bruno Silva-Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sofia Mensurado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Silva-Santos.

Ethics declarations

Competing interests

The authors receive funding support from Takeda Development Center Americas, Inc. (Lexington, MA, USA).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Silva-Santos, B., Mensurado, S. γδ T cells maintain sensitivity to immunotherapy in MHC-I-deficient tumors. Nat Immunol 24, 387–388 (2023). https://doi.org/10.1038/s41590-023-01429-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01429-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer